CIP2A Antibody (HL1916): sc-80661
- CIP2A Antibody (HL1916) is a mouse monoclonal IgG2b κ, cited in 1 publications, provided at 200 µg/ml
- raised against C-terminal CIP2A of human origin
- recommended for detection of CIP2A of human origin by WB, IP and IF
- See CIP2A (HL1925): sc-80662 for CIP2A antibody conjugates, including AC, HRP, FITC, PE, Alexa Fluor® 488, 594, 647, 680 and 790.
- m-IgG2b BP-HRP is the preferred secondary detection reagent for CIP2A Antibody (HL1916) for WB applications. This reagent is now offered in a bundle with CIP2A Antibody (HL1916) (see ordering information below).
QUICK LINKS
SEE ALSO...
CIP2A Antibody (HL1916) is a mouse monoclonal IgG2b antibody that detects CIP2A in human samples through applications such as western blotting (WB), immunoprecipitation (IP), and immunofluorescence (IF). CIP2A, also known as cancerous inhibitor of protein phosphatase 2A or p90 autoantigen, is a single-pass membrane protein that plays a pivotal role in oncogenesis by inhibiting protein phosphatase 2A (PP2A) activity. PP2A inhibition is significant as PP2A regulates various cellular processes, including cell growth and division, and PP2A inactivation leads to c-Myc stabilization, an oncogenic transcription factor driving tumor formation and malignant cell proliferation. CIP2A′s structure allows specific interaction with PP2A′s catalytic subunit, effectively blocking dephosphorylation activity. Such interaction facilitates human cell transformation by promoting phosphorylated c-Myc accumulation and oncogenic signaling pathways. CIP2A overexpression occurs frequently in several cancer types, including colon, gastric, and head and neck squamous cell carcinomas, highlighting CIP2A′s potential as a biomarker and therapeutic target in cancer research.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
CIP2A Antibody (HL1916) References:
- Oncogenic nexus of cancerous inhibitor of protein phosphatase 2A (CIP2A): an oncoprotein with many hands. | De, P., et al. 2014. Oncotarget. 5: 4581-602. PMID: 25015035
- CIP2A overexpression induces autoimmune response and enhances JNK signaling pathway in human lung cancer. | Peng, B., et al. 2015. BMC Cancer. 15: 895. PMID: 26560124
- Knockdown of CIP2A sensitizes ovarian cancer cells to cisplatin: an in vitro study. | Zhang, X., et al. 2015. Int J Clin Exp Med. 8: 16941-7. PMID: 26629248
- CIP2A mediates fibronectin-induced bladder cancer cell proliferation by stabilizing β-catenin. | Gao, F., et al. 2017. J Exp Clin Cancer Res. 36: 70. PMID: 28521777
- CIP2A Constrains Th17 Differentiation by Modulating STAT3 Signaling. | Khan, MM., et al. 2020. iScience. 23: 100947. PMID: 32171124
- Effect of CIP2A and its mechanism of action in the malignant biological behavior of colorectal cancer. | Chen, W., et al. 2020. Cell Commun Signal. 18: 67. PMID: 32321509
- Exploring CIP2A modulators using multiple molecular modeling approaches. | Bhowmick, S., et al. 2022. J Biomol Struct Dyn. 40: 1048-1063. PMID: 32930061
- Cip2A modulates osteogenic differentiation via the ERK-Runx2 pathway in MG63 cells. | Son, HE. and Jang, WG. 2021. Biofactors. 47: 658-664. PMID: 34077593
- Reciprocal regulation of CIP2A and AR expression in prostate cancer cells. | Chuang, HW., et al. 2022. Discov Oncol. 13: 87. PMID: 36098827
- Cancer progression by the okadaic acid class of tumor promoters and endogenous protein inhibitors of PP2A, SET and CIP2A. | Fujiki, H., et al. 2023. J Cancer Res Clin Oncol. 149: 9425-9433. PMID: 37097392
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
CIP2A Antibody (HL1916) | sc-80661 | 200 µg/ml | $322.00 | |||
CIP2A Antibody (HL1916): m-IgG2b BP-HRP Bundle | sc-548466 | 200 µg Ab; 10 µg BP | $361.00 |